How Recent Clinical Progress Is Rewriting the Story for Invivyd [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
a modest shift in perceived risk as the REVOLUTION program for VYD2311 advances. Analysts largely interpret the stable long term revenue growth outlook as confirmation that new clinical data is reinforcing, not rewriting, expectations for how VYD2311 could reshape Invivyd's market opportunity. Read on to see how investors can track these evolving assumptions and stay ahead of future narrative shifts around the stock. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Invivyd. ?? Bullish Takeaways H.C. Wainwright analyst Patrick Trucchio doubled his price target on Invivyd to $10 from $5, underscoring a more constructive view on valuation relative to prior expectations. The firm characterizes the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point, signaling improved confidence in Invivyd's execution and long term growth prospects in COVID 19 prevention. Maintaining a Buy rati
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- A Look at Invivyd (IVVD) Valuation After Advancing VBY329 RSV Antibody Candidate into Preclinical Development [Yahoo! Finance]Yahoo! Finance
- Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Invivyd (NASDAQ:IVVD) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.MarketBeat
- Invivyd (NASDAQ:IVVD) had its "hold" rating reaffirmed by analysts at D. Boral Capital.MarketBeat
IVVD
Earnings
- 11/6/25 - Miss
IVVD
Sec Filings
- 11/25/25 - Form SCHEDULE
- 11/24/25 - Form 8-K
- 11/20/25 - Form 4
- IVVD's page on the SEC website